In breast cancer, CD133 expression indicates CSC-like characteristics and tumourigenic effects, with increased tumour self-renewal, high tumour cell proliferation, and drug resistance, confirming the prognostic significance of CD133 [25, 26]. The gene discussed is PROM1; the disease is breast cancer.